Ga-68 PSMA PET/CT: Physics, Quantification, and Quality Control

Ga-68 PSMA PET/CT images prostate cancer by binding prostate-specific membrane antigen, and its physics — a 68-minute half-life, high-energy positrons, and on-site generator production — shapes the entire imaging and quality-control workflow. A defensible program must control the radiopharmaceutical (radiochemical and radionuclidic purity, Ge-68 breakthrough), the scanner (NEMA NU-2 performance and SUV calibration), and the interpretation (standardized PSMA-RADS or E-PSMA reporting), because each link affects whether the SUV and the report can be trusted.¹²

Prostate-specific membrane antigen (PSMA) PET has rapidly become a backbone of prostate cancer imaging. The prospective, randomized proPSMA study showed Ga-68 PSMA-11 PET/CT was 27% more accurate than combined CT and bone scan for detecting nodal or distant metastases in high-risk disease, with less radiation exposure and more frequent management change.³ But the clinical value of any PSMA scan rests on the underlying physics and quality control — and Ga-68 brings a specific set of constraints that a qualified medical physicist must understand and document.

Introduction

PSMA is a transmembrane glycoprotein (glutamate carboxypeptidase II) that is overexpressed on the surface of most prostate cancer cells, with expression tending to increase in higher-grade and castration-resistant disease. Small-molecule PSMA ligands labeled with a positron emitter bind this target, so PET/CT can map prostate cancer throughout the body. The most widely used Ga-68 agent is Ga-68 PSMA-11 (gozetotide), available through FDA-approved cold kits including Locametz and Illuccix.¹⁴⁵

Ga-68 PSMA PET/CT is used to stage high-risk disease before curative-intent treatment, to localize biochemical recurrence when PSA rises after surgery or radiotherapy, and to select and monitor patients for PSMA-targeted radioligand therapy.¹³⁶ This guide focuses on the physics and quality-control angle: why Ga-68 behaves the way it does, how it compares with F-18 PSMA agents, how the agent is produced and tested, how the SUV quantification chain is held together, and how scanner performance and reporting frameworks keep the result defensible.

DRPS supports nuclear medicine and PET/CT programs across Florida, Maryland, Virginia, Washington DC, California, and Nevada with PET/CT and nuclear medicine physics and accreditation support. For the radionuclide context behind this article, see our overview of common PET and radiopharmaceutical-therapy isotopes.

Topic Explanation

What is Ga-68 PSMA PET/CT?

Ga-68 PSMA PET/CT is a molecular imaging exam in which a gallium-68-labeled PSMA-targeting ligand is injected, allowed to localize to PSMA-expressing tissue, and imaged on a PET/CT scanner that records the paired 511 keV annihilation photons. The CT provides attenuation correction and anatomic localization; the PET provides the functional map of PSMA expression, often quantified by standardized uptake value (SUV).

Several terms recur throughout this guide:

• PSMA-11 (gozetotide) — the most common Ga-68 PSMA ligand, formed by chelating Ga-68 to the HBED-CC-conjugated PSMA inhibitor in an approved cold kit.⁴⁵
• Positron range — the distance a positron travels in tissue from emission to annihilation; longer range degrades the best achievable spatial resolution.
• SUV — a semi-quantitative measure of tracer concentration normalized to injected activity and body size.
• Ge-68 breakthrough — the small amount of long-lived germanium-68 parent that can pass into the eluate from a generator, controlled by a radionuclidic-purity specification.

Why does the radionuclide matter so much?

In PET, the radionuclide sets the half-life (which drives logistics and decay correction), the positron branching ratio and energy (which drive image counts and intrinsic resolution), and the production route (which drives availability and on-site quality control). Ga-68 and F-18 both produce the same 511 keV annihilation photons that the scanner detects, but they differ in every one of those upstream properties — which is why the choice between a Ga-68 and an F-18 PSMA agent is partly a physics and operations decision, not only a clinical one.¹²

The same source-and-workflow logic that governs PET/CT shielding also governs PSMA imaging quality: the answer depends on the radionuclide, the activity handled, and the actual clinical process, not on the scanner alone. For the facility-design side of that, see our PET/CT shielding calculations guide.

Key Technical Principles

Ga-68 versus F-18 PSMA agents

Ga-68 decays predominantly by positron emission (about 89% positron branching) with a physical half-life of roughly 68 minutes. Its positrons are relatively energetic — a maximum energy near 1.9 MeV and a higher mean energy than F-18 — so they travel farther before annihilating. F-18, by contrast, has a longer 110-minute half-life and low-energy positrons (maximum near 0.63 MeV), giving it a shorter positron range and the potential for slightly sharper intrinsic resolution and cyclotron-scale distribution.²⁷ The clinical trials behind the major agents bear this out across both chemistries: Ga-68 PSMA-11 (proPSMA) and the F-18 agent piflufolastat F-18 / DCFPyL (OSPREY, CONDOR) all demonstrated strong diagnostic performance in their target settings.³⁶⁸

These decay-data values are confirmed against standard NNDC/DDEP and ICRP Publication 128 references: Ga-68 positron branching is about 89% (88.91%) with a maximum positron energy near 1.9 MeV (1.899 MeV), while F-18 has a maximum positron energy near 0.63 MeV (0.634 MeV).

The practical takeaway: F-18 agents can offer logistical reach and a small intrinsic-resolution advantage from shorter positron range, while Ga-68 PSMA-11 enables decentralized, generator-based production without a cyclotron. Both are clinically validated; the right choice depends on the program's volume, geography, regulatory authorizations, and quality system.¹²

Ga-68 decay and decay correction

Because Ga-68 has a short half-life, decay correction is unforgiving — small timing errors produce real activity errors. Activity at time $t$ follows the standard exponential decay law:

where $A_0$ is the activity at the reference time and $\lambda$ is the decay constant. The decay constant is set by the half-life $T_{1/2}$:

A single half-life therefore removes half the activity in just over an hour. Over a typical ~30-40 minute interval between calibration, injection, and acquisition, the correction is large, so the injection time must be recorded accurately and applied consistently between the dose calibrator and the scanner. An error of a few minutes in recorded injection time biases the decay-corrected activity — and therefore the SUV — by a few percent.

Positron range and intrinsic resolution

The longer positron range of Ga-68 is the main reason it cannot quite match the best intrinsic resolution of F-18. A 511 keV photon pair is created where the positron annihilates, not where the nucleus decayed, so the average annihilation displacement adds a blur term to the system point-spread function. Conceptually, the intrinsic resolution combines in quadrature:

where $r_{\text{detector}}$ is the detector/crystal contribution, $r_{\text{range}}$ is the positron-range blur (larger for Ga-68), and $r_{\text{noncolinearity}}$ accounts for the slight departure from exactly 180° between annihilation photons. In modern clinical PET, detector size and reconstruction often dominate the delivered resolution, so the Ga-68 range penalty is modest in practice — but it is real, it is larger in low-density tissue such as lung, and it is one reason scanner performance and reconstruction settings deserve scrutiny in a quantitative PSMA program.²⁷

The SUV quantification chain

SUV is only as trustworthy as the calibration chain behind it. For a body-weight-normalized SUV, the working definition is:

where $C_{\text{tissue}}$ is the decay-corrected activity concentration in the region of interest (e.g., kBq/mL), $A_{\text{injected}}$ is the net injected activity decay-corrected to the scan reference time, and $W$ is patient body weight. Every quantity in that expression is a potential error source:

• $C_{\text{tissue}}$ depends on the scanner's absolute calibration to a traceable activity source and on correct attenuation and scatter correction.
• $A_{\text{injected}}$ depends on the dose calibrator being cross-calibrated to the scanner, accurate residual-activity measurement in the syringe, and the correct injection time for decay correction.
• $W$ must be the patient's actual weight at the time of the scan.

A break anywhere in that chain biases SUV directly and silently. This is why cross-calibration between the dose calibrator and the PET scanner is a recurring requirement in quantitative imaging programs, and why dose-calibrator performance is itself a QC obligation — see our guide to dose calibrator quality control. Uptake time also matters: PSMA uptake and background clearance evolve after injection, so a consistent uptake interval supports comparable SUVs across visits, a point we develop in PET imaging uptake time.

Clinical Impact

The physics and QC choices above translate directly into clinical reliability. When the calibration chain is intact and the scanner performs to specification, SUV trends can support staging, response assessment, and theranostic patient selection. When it is not, errors masquerade as biology.

The clinical evidence base is strong. In high-risk prostate cancer, the prospective randomized proPSMA study found Ga-68 PSMA-11 PET/CT had 92% accuracy versus 65% for conventional CT and bone scan for nodal or distant disease, with higher reporter agreement and lower radiation dose.³ For the F-18 agent piflufolastat F-18, the OSPREY study met its specificity endpoint for pelvic nodal staging with high positive predictive value, and the CONDOR study demonstrated a high correct-localization rate in biochemically recurrent disease with negative conventional imaging, frequently changing intended management.⁶⁸ Ga-68 PSMA imaging also underpins patient selection for PSMA-directed radioligand therapy, tying diagnostic quality to therapeutic decisions in the theranostic pathway.¹

Physiologic uptake and pitfalls are part of the clinical picture and depend on understanding the agent's biodistribution. Normal PSMA-ligand uptake is expected in salivary and lacrimal glands, liver, spleen, small bowel, and kidneys, with urinary excretion that can obscure or mimic pelvic disease. Benign causes of uptake — such as celiac ganglia, certain bone lesions, and inflammatory nodes — are well described and are precisely why standardized reporting frameworks exist. The interpreting physician and physicist should know the expected biodistribution before attributing a focus to malignancy.¹²

Practical Optimization Tips

Production and on-site radiochemistry

Ga-68 for PSMA-11 is most often produced by eluting a Ge-68/Ga-68 generator on site. The parent germanium-68 has a long half-life (about 271 days), so a single generator supplies gallium-68 for months; the eluted Ga-68 is then combined with the PSMA-11 cold kit (Locametz or Illuccix) and reacted to form the labeled product.⁴⁵ Some programs instead use cyclotron-produced Ga-68 or switch to an F-18 PSMA agent for distribution reach. Practical points:

• Elution yield declines over the generator's life; track yield and breakthrough trends.
• The short half-life caps how many patient doses one elution supports — schedule accordingly.
• On-site production makes the facility a manufacturer of the final dose, so the quality system, not just the scanner, is in scope.

Radiopharmaceutical quality control

Each prepared batch should be tested per the kit prescribing information and applicable pharmacopeial standards (for example, USP and Ph. Eur. monographs and the EANM radiopharmacy guidance) before release. Core tests typically include:⁴⁵⁹¹⁰

• Radiochemical purity — usually by thin-layer chromatography (TLC/iTLC) or HPLC, confirming the Ga-68 is bound to PSMA-11 rather than free Ga-68 or colloid. Our primer on radiochemical purity and TLC quality control covers the method in depth.
• Radionuclidic purity / Ge-68 breakthrough — confirming that long-lived Ge-68 in the final product is within the specified limit, a control conceptually parallel to molybdenum breakthrough in a Tc-99m generator (see Tc-99m generators and breakthrough QC).
• pH, appearance, and radiochemical identity, plus any kit-specified checks.

For the FDA-approved kits, the confirmed release specifications are a radiochemical purity of at least 95% and a Ge-68 breakthrough limit of no more than 0.001% of the total radioactivity (⁶⁸Ge/⁶⁸Ga ratio ≤ 1×10⁻³), with breakthrough tested weekly. Note the kit-specific nuance: the ≤0.001% breakthrough limit is specified in the Illuccix prescribing information, whereas the Locametz label's release-test table lists only appearance, pH, and radiochemical purity and defers the Ge-68 breakthrough limit to the generator manufacturer's instructions for use. Always verify the exact limit and method against the prescribing information for the kit and generator in use.

Scanner performance and SUV calibration

A quantitative PSMA program should hold scanner performance and SUV calibration to documented standards:

• Cross-calibrate the PET scanner and the dose calibrator on a defined schedule using a traceable source, and verify the SUV calibration with a uniform phantom.
• Standardize the protocol — injected activity, uptake time, acquisition, and reconstruction — so SUVs are comparable across visits and, ideally, across scanners.
• Confirm acquisition-mode performance through periodic NEMA NU-2 testing, which characterizes sensitivity, spatial resolution, noise-equivalent count rate (NECR), scatter fraction, and image quality.¹⁴ Our guide to PET/CT performance testing with NEMA NU-2 walks through these metrics, and time-of-flight reconstruction — covered in the technical advantage of TOF in PET — improves effective signal-to-noise for the relatively count-limited Ga-68 acquisition.

Common pitfalls to avoid

• Sloppy injection-time recording. With a 68-minute half-life, a few minutes of timing error is a few percent of SUV error.
• Ignoring residual activity. Uncounted syringe residual inflates the assumed injected activity and biases SUV downward.
• Skipping cross-calibration. A scanner and dose calibrator that drift apart silently corrupt every SUV.
• Treating Ga-68 like F-18 for resolution. The longer positron range means reconstruction and small-lesion expectations differ slightly.
• Releasing without complete QC. On-site production makes radiochemical and radionuclidic purity, including Ge-68 breakthrough, release-gating tests, not optional add-ons.
• Free-text reporting. Unstructured reads reduce reproducibility; standardized frameworks improve agreement.¹¹¹²

Regulatory Considerations

A Ga-68 PSMA program sits at the intersection of radioactive-material licensing, radiopharmaceutical quality standards, and imaging performance standards. Each must be addressed and documented.

• Medical use of byproduct material. Ga-68 is byproduct material; possession and medical use fall under 10 CFR Part 35 (or the equivalent Agreement State program), with dose limits under 10 CFR Part 20. Of the states DRPS serves, Florida, Maryland, Virginia, California, and Nevada are NRC Agreement States that license medical use under their own radiation-control rules, while Washington, DC is regulated directly by the NRC. Generator possession, elution, and on-site preparation should be reflected in the license and the radiation safety program. For licensing mechanics, see our NRC radioactive material license guide.
• Radiopharmaceutical quality. On-site preparation should follow the FDA-approved kit prescribing information (Locametz, Illuccix), applicable USP and Ph. Eur. monographs, and EANM radiopharmacy guidance, with documented release testing.⁴⁵⁹¹⁰
• Imaging performance and accreditation. Quantitative PSMA imaging benefits from NEMA NU-2 performance characterization and from accreditation-program requirements for calibration, phantom QC, and physicist oversight. DRPS provides this through accreditation support and medical physicist consulting.
• Acquisition and interpretation standards. The joint SNMMI/EANM PSMA PET/CT procedure standard/guideline (v2.0) defines indications, acquisition, and interpretation; PSMA-RADS and E-PSMA provide standardized, validated reporting frameworks with demonstrated interobserver agreement.^1111213

Aligning the program with these frameworks — and documenting the calibration chain, QC records, and reporting structure — is what makes a PSMA service defensible during accreditation review and inspection.

Frequently Asked Questions (FAQs)

What is Ga-68 PSMA PET/CT used for?

Ga-68 PSMA PET/CT images prostate cancer by targeting prostate-specific membrane antigen, a protein overexpressed on most prostate cancer cells. It is used for staging high-risk disease before treatment, localizing biochemical recurrence after rising PSA, and selecting patients for PSMA-targeted radioligand therapy.¹³

Why does Ga-68 give slightly lower spatial resolution than F-18?

Ga-68 emits higher-energy positrons than F-18, so they travel farther in tissue before annihilating. This longer positron range blurs the point at which the 511 keV photon pair originates, degrading the best achievable intrinsic spatial resolution compared with F-18 agents such as piflufolastat F-18.²⁷

How is Ga-68 produced for PSMA imaging?

Ga-68 is eluted on-site from a Ge-68/Ga-68 generator, where long-lived germanium-68 (about a 271-day half-life) continuously produces gallium-68. The eluate is then radiolabeled to PSMA-11 (gozetotide) using an FDA-approved kit such as Locametz or Illuccix. Some centers instead use cyclotron-produced Ga-68 or an F-18 PSMA agent.⁴⁵

What radiopharmaceutical quality control does Ga-68 PSMA require?

Each batch should be checked for radiochemical purity (typically by thin-layer or high-performance liquid chromatography), radionuclidic purity including Ge-68 breakthrough, pH, appearance, and radiochemical identity, consistent with the manufacturer's kit instructions and applicable pharmacopeial standards before release.⁴⁵⁹¹⁰

What is the Ge-68 breakthrough limit?

Pharmacopeial and kit specifications limit germanium-68 breakthrough in the final product, commonly expressed as a small fraction of the gallium-68 activity at administration. The exact acceptance limit and test method are defined by the kit prescribing information and the applicable pharmacopeia, and must be verified for each product and generator.⁴⁵⁹

How is SUV kept reliable on a PSMA PET scanner?

SUV depends on an unbroken calibration chain: a scanner well-calibrated to a traceable source, a dose calibrator cross-calibrated to the scanner, accurate injected-activity and residual measurement, correct injection time and patient weight, and proper decay correction. Errors anywhere in that chain bias SUV directly.²

Does Ga-68 PSMA PET replace conventional staging imaging?

In high-risk prostate cancer, prospective evidence shows PSMA PET/CT is more accurate than combined CT and bone scan for detecting nodal and distant disease and more often changes management, but the appropriate use, protocol, and interpretation should follow current procedure standards and the clinical context.¹³

Key Takeaways

• The radionuclide drives the workflow. Ga-68's ~68-minute half-life, ~89% positron branching, and high positron energy set the logistics, decay correction, and resolution limits of a PSMA program.²³
• Positron range costs a little resolution. Higher-energy Ga-68 positrons travel farther before annihilation, adding a modest blur term relative to F-18 agents — real, but often subordinate to detector size and reconstruction.²⁷
• On-site generators make you a manufacturer. Ge-68/Ga-68 generator elution plus kit labeling brings radiochemical and radionuclidic purity, including Ge-68 breakthrough, into the release-testing scope.⁴⁵⁹
• SUV is a chain, not a number. Scanner calibration, dose-calibrator cross-calibration, residual activity, injection time, weight, and decay correction must all be correct for SUV to mean anything.
• Performance and reporting must be standardized. NEMA NU-2 testing supports scanner performance; SNMMI/EANM, PSMA-RADS, and E-PSMA standardize acquisition and interpretation with demonstrated reproducibility.^1111213

Conclusion

Ga-68 PSMA PET/CT has transformed prostate cancer imaging, but its clinical power rests on disciplined physics and quality control. The short half-life makes decay correction and timing critical; the energetic positrons impose a small but real resolution penalty; on-site generator production turns the facility into a manufacturer with radiochemical, radionuclidic, and breakthrough obligations; and the SUV is only as good as the weakest link in its calibration chain. Layered on top, NEMA NU-2 performance testing and standardized SNMMI/EANM, PSMA-RADS, and E-PSMA frameworks keep both the measurement and the report reproducible.

A program that treats these as one integrated quality system — agent, scanner, and interpretation together — produces PSMA studies that clinicians can trust for staging, recurrence localization, and theranostic selection, and that hold up under accreditation review and regulatory inspection.

How DRPS Can Help

Diagnostic Radiation Physics Services helps PET/CT and nuclear medicine programs build defensible quantitative imaging. For Ga-68 PSMA services, this can include PET/CT and nuclear medicine physics support, scanner-to-dose-calibrator cross-calibration and SUV verification, NEMA NU-2 performance testing, radiopharmaceutical QC program review, accreditation support, radioactive material license support, and medical physicist consulting aligned with NRC and Agreement State requirements.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, and Nevada. A strong PSMA program is not just about acquiring images — it is about making the trustworthy result the routine result for the clinical team.

Related Resources

• Common PET & RPT isotopes
• PET imaging uptake time
• PET/CT performance testing with NEMA NU-2
• The technical advantage of TOF in PET imaging
• Radiochemical purity and TLC quality control
• Dose calibrator quality control
• PET/CT and nuclear medicine physics
• Accreditation support

References

1. Fendler WP, Eiber M, Beheshti M, et al. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. European Journal of Nuclear Medicine and Molecular Imaging. 2023;50(5):1466-1486. doi:10.1007/s00259-022-06089-w. doi.org
2. Society of Nuclear Medicine and Molecular Imaging. The basics of PET physics and instrumentation and SNMMI PET resources. snmmi.org
3. Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208-1216. doi:10.1016/S0140-6736(20)30314-7. doi.org
4. U.S. Food and Drug Administration. Locametz (gallium Ga 68 gozetotide) prescribing information. accessdata.fda.gov
5. U.S. Food and Drug Administration. Illuccix (kit for the preparation of gallium Ga 68 gozetotide injection) prescribing information. accessdata.fda.gov
6. Morris MJ, Rowe SP, Gorin MA, et al. Diagnostic performance of 18F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study. Clinical Cancer Research. 2021;27(13):3674-3682. doi:10.1158/1078-0432.CCR-20-4573. doi.org
7. International Commission on Radiological Protection. ICRP Publication 128: Radiation Dose to Patients from Radiopharmaceuticals — A Compendium of Current Information Related to Frequently Used Substances. Annals of the ICRP. 2015;44(2 Suppl). icrp.org
8. Pienta KJ, Gorin MA, Rowe SP, et al. A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate-specific membrane antigen PET/CT with 18F-DCFPyL in prostate cancer patients (OSPREY). The Journal of Urology. 2021;206(1):52-61. doi:10.1097/JU.0000000000001698. doi.org
9. The United States Pharmacopeial Convention. USP <823> Positron Emission Tomography Drugs for Compounding, Investigational, and Research Uses; gallium Ga 68 radiopharmaceutical monographs. usp.org
10. European Association of Nuclear Medicine. Guidance on current good radiopharmacy practice (cGRPP) and radiopharmacy committee guidelines. eanm.org
11. Ceci F, Oprea-Lager DE, Emmett L, et al. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. European Journal of Nuclear Medicine and Molecular Imaging. 2021;48(5):1626-1638. doi:10.1007/s00259-021-05245-y. doi.org
12. Werner RA, Hartrampf PE, Fendler WP, et al. Prostate-specific membrane antigen reporting and data system version 2.0. European Urology. 2023;84(5):491-502. doi:10.1016/j.eururo.2023.06.008. doi.org
13. Werner RA, Bundschuh RA, Bundschuh L, et al. Interobserver agreement for the standardized reporting system PSMA-RADS 1.0 on 18F-DCFPyL PET/CT imaging. Journal of Nuclear Medicine. 2018;59(12):1857-1864. doi:10.2967/jnumed.118.217588. doi.org
14. National Electrical Manufacturers Association. NEMA NU 2: Performance Measurements of Positron Emission Tomographs (PET). Rosslyn, VA: NEMA. nema.org